Baricitinib for Refractory Takayasu Arteritis
Baricitinib for Takayasu Arteritis Refractory to TNF-α Inhibitors: a Prospective Pilot Open-label Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Department of Rheumatology and Immunology, Peking University People's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female aged 18-70 years at time of screening.
- Diagnosis of Takayasu arteritis (according to the 2022 ACR/EULAR) for ≥3 months before screening.
- Active Takayasu arteritis at time of screening (NIH score≥2).
- Resistant to traditional therapies and anti-TNF-α therapy for at least 12 months.
- Given their written informed consent to participate in the trial and expected to be able to adhere to the study visit schedule and other protocol requirements.
Exclusion Criteria:
- TKA-related active major organ involvement requiring immunosuppressive therapy, e.g., pulmonary (e.g., pulmonary artery aneurysm), vascular (e.g., thrombophlebitis, recurrent malignant aneurysms), gastrointestinal (e.g., gastrointestinal ulcers), and central nervous system (e.g., meningoencephalitis).
- High-dose glucocorticoid (>1mg/kg/d) usage within 1 month.
- Severe comorbidities: including heart failure (≥ grade III NYHA), renal insufficiency (creatinine clearance ≤30 ml/min), hepatic insufficiency (serum ALT or AST >3 times the ULN, or total bilirubin >ULN for the central laboratory conducting the test). Other severe, progressive or uncontrolled hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease (including demyelinating diseases such as multiple sclerosis).
- Known allergies, hypersensitivity, or intolerance to Baricitinib or its excipients.
- Had a severe infection (including, but not limited to hepatitis, pneumonia, sepsis, or pyelonephritis); had been hospitalized for an infection; or had been treated with IV antibiotics for an infection, within 2 months prior to the first administration of study agent.
- Chest radiograph within 3 months prior to the first administration of study agent that showed an abnormality suggestive of a malignancy or current active infection, including tuberculosis.
- Infected with HIV (positive serology for HIV antibody) or hepatitis C (positive serology for Hep C antibody). If seropositive, consultation with a physician with expertise in the treatment of HIV or hepatitis C virus infection was recommended.
- Infected with hepatitis B virus. For patients who were not eligible for this study due to hepatitis B virus test results, consultation with a physician with expertise in the treatment of hepatitis B virus infection was recommended.
- Had any known malignancy or has a history of malignancy within the previous 5 years (with the exception of a nonmelanoma skin cancer that had been treated with no evidence of recurrence for ≥3 months before the first study agent administration or cervical neoplasia with surgical cure).
- Had uncontrolled psychiatric or emotional disorder, including a history of drug and alcohol abuse within the past 3 years that might prevent the successful completion of the study.
- Received, or was expected to receive, any live virus or bacterial vaccination within 3 months before the first administration of study agent, during the study, or within 4 months after the last administration of study agent. Had a BCG vaccination within 12 months of screening.
- Pregnancy, lactation or women of child-bearing potential (WCBP) unwilling to use medically approved contraception whilst receiving treatment and for 12 months after treatment has finished.
- Men whose partners are of child-bearing potential but who are unwilling to use appropriate medically approved contraception whilst receiving treatment and for 12 months after treatment has finished.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Treated with baricitinib
Ten patients with Takayasu arteritis refractory TNF-α inhibirors were treated with baricitinib.
|
The patients received Baricitinib for 48 weeks.
The method is to take Baricitinib 4mg every day for a period of 48 weeks.
All the patients will be followed up prospectively for 48 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients achieving complete remission and partial remission
Time Frame: Week 24
|
The primary endpoint was defined as the proportion(percent) of patients in the whole cohort achieving complete remission and partial remission by week 24.
|
Week 24
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes of National Institutes of Health (NIH) score of patients
Time Frame: Week 24 and week 48
|
The manifestations, imaging findings and laboratory parametes were recorded during the follow-up.
The disease activity of patients were accessed by National Institutes of Health (NIH) score.
(Range: 0~4, higher scores mean higher disease activity)
|
Week 24 and week 48
|
|
Changes of Indian Takayasu Clinical Activity Score (ITAS2010) of patients
Time Frame: Week 24 and week 48
|
The manifestations, imaging findings and laboratory parameters were recorded during the follow-up.
The disease activity of patients were accessed by Indian Takayasu Clinical Activity Score (ITAS2010).
(Range: 0~51, higher scores mean higher disease activity)
|
Week 24 and week 48
|
|
Changes of C-reactive protein
Time Frame: Week 24 and week 48
|
Blood samples were collected from all patients and the concentration of C-reactive protein (mg/L) were recorded.
|
Week 24 and week 48
|
|
Changes of erythrocyte sedimentation rate
Time Frame: Week 24 and week 48
|
Blood samples were collected from all patients and the erythrocyte sedimentation rates (mm/h) were recorded.
|
Week 24 and week 48
|
|
Changes of dosage of glucocorticoids from baseline.
Time Frame: Week 24 and week 48
|
The dosage of glucocorticoids (mg/day) of all patients were recorded during the follow-up.
|
Week 24 and week 48
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- PKU People's Hospital
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.